JP2014526881A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526881A5
JP2014526881A5 JP2014515207A JP2014515207A JP2014526881A5 JP 2014526881 A5 JP2014526881 A5 JP 2014526881A5 JP 2014515207 A JP2014515207 A JP 2014515207A JP 2014515207 A JP2014515207 A JP 2014515207A JP 2014526881 A5 JP2014526881 A5 JP 2014526881A5
Authority
JP
Japan
Prior art keywords
protein
ubiquitin
heterodimeric
modified
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014515207A
Other languages
English (en)
Japanese (ja)
Other versions
JP6146821B2 (ja
JP2014526881A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/061455 external-priority patent/WO2012172055A1/en
Publication of JP2014526881A publication Critical patent/JP2014526881A/ja
Publication of JP2014526881A5 publication Critical patent/JP2014526881A5/ja
Application granted granted Critical
Publication of JP6146821B2 publication Critical patent/JP6146821B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014515207A 2011-06-15 2012-06-15 修飾ユビキチンに基づく二量体型結合タンパク質 Active JP6146821B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11170054.8 2011-06-15
EP11170054 2011-06-15
PCT/EP2012/061455 WO2012172055A1 (en) 2011-06-15 2012-06-15 Dimeric binding proteins based on modified ubiquitins

Publications (3)

Publication Number Publication Date
JP2014526881A JP2014526881A (ja) 2014-10-09
JP2014526881A5 true JP2014526881A5 (https=) 2015-05-28
JP6146821B2 JP6146821B2 (ja) 2017-06-14

Family

ID=44680786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014515207A Active JP6146821B2 (ja) 2011-06-15 2012-06-15 修飾ユビキチンに基づく二量体型結合タンパク質

Country Status (8)

Country Link
US (1) US9492572B2 (https=)
EP (1) EP2721152B1 (https=)
JP (1) JP6146821B2 (https=)
AU (1) AU2012268970B2 (https=)
CA (1) CA2837804C (https=)
DK (1) DK2721152T3 (https=)
IL (1) IL229722A (https=)
WO (1) WO2012172055A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4088742B2 (ja) 2000-12-26 2008-05-21 信越化学工業株式会社 フォトマスクブランクス、フォトマスク及びフォトマスクブランクスの製造方法
JP2002244274A (ja) 2001-02-13 2002-08-30 Shin Etsu Chem Co Ltd フォトマスクブランク、フォトマスク及びこれらの製造方法
EP1859028B1 (en) * 2005-02-10 2015-12-02 Regents Of The University Of Minnesota Vascular endothelial cells
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH 新規なegfr結合タンパク質
WO2016124670A1 (en) 2015-02-06 2016-08-11 Scil Proteins Gmbh Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
JP6856938B2 (ja) 2015-07-16 2021-04-14 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH 新規な免疫グロブリン結合タンパク質およびアフィニティ精製におけるそれらの使用
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
US11813336B2 (en) 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CN109963864B (zh) 2016-08-11 2024-01-02 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
MX2021007283A (es) 2018-12-18 2021-07-15 Navigo Proteins Gmbh Proteinas de union especificas del folr1 novedosas para diagnostico y tratamiento del cancer.
JP7854204B2 (ja) * 2020-11-09 2026-05-01 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ii型コラーゲン結合タンパク質
KR20250090347A (ko) * 2022-10-24 2025-06-19 나피고 프로타인스 게엠베하 프로그램화 사멸 리간드 1 (pd-l1)에 대한 높은 결합 친화도를 갖는 신규한 단백질

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5958684A (en) 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
WO1998054312A1 (en) 1997-05-28 1998-12-03 Babraham Institute Ribosome complexes as selection particles for in vitro display and evolution of proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030045681A1 (en) 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
AU2001239470A1 (en) 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
JP2003524018A (ja) 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
US6799121B2 (en) 2000-03-30 2004-09-28 York University Sequencing of peptides by mass spectrometry
US20110179531A1 (en) 2000-05-09 2011-07-21 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US20040043386A1 (en) 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
AU2003250972A1 (en) 2003-07-14 2005-01-28 Mattex Leisure Industries Artificial turf filament and artificial turf system
WO2005044845A2 (en) 2003-11-04 2005-05-19 Yale University Protein binding miniature proteins
US7393918B2 (en) 2003-12-11 2008-07-01 Yale University Protein binding miniature proteins and uses thereof
DE10360483B4 (de) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
CA2607954A1 (en) 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
ATE463512T1 (de) 2005-11-09 2010-04-15 Morphosys Ag Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
CA2648484A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
RU2553333C2 (ru) * 2009-12-14 2015-06-10 Сцил Протеинс Гмбх Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
EP2861616A1 (en) 2012-06-13 2015-04-22 Scil Proteins GmbH Human fusion proteins comprising single chain tnfalpha and targeting domains

Similar Documents

Publication Publication Date Title
JP2014526881A5 (https=)
US12599652B2 (en) Serum albumin-binding fibronectin type III domains
JP6529952B2 (ja) 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
HK1200842A1 (en) Proteins with improved half-life and other properties
JP2015212284A5 (https=)
JP6146821B2 (ja) 修飾ユビキチンに基づく二量体型結合タンパク質
JP2010534486A5 (https=)
RU2012114662A (ru) Модифицированные убиквитиновые белки со специфической связывающей активностью для экстрадомена "в" фибронектина
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
JP2015525217A5 (https=)
JP2016000731A5 (https=)
JP2018522563A5 (https=)
JP2020501550A5 (https=)
JP2015509707A5 (https=)
JP2019507589A5 (https=)
JP2016500648A5 (https=)
JP2014523238A5 (https=)
JP2015530404A5 (https=)
CN102781960A (zh) Hsa相关组合物及使用方法
JP2015193653A (ja) プロタンパク質およびその使用方法
JP2009509535A5 (https=)
JP2017514522A5 (https=)
JP2015134758A5 (https=)
JP2016508143A5 (https=)
JP2015524403A5 (https=)